# Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)

> **NCT01284582** · PHASE1 · COMPLETED · sponsor: **Affiris AG** · enrollment: 36 (actual)

## Conditions studied

- HDL
- Drug Safety

## Interventions

- **BIOLOGICAL:** ATH03

## Key facts

- **NCT ID:** NCT01284582
- **Lead sponsor:** Affiris AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2012-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01284582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01284582, "Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01284582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*